Literature DB >> 14990969

K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung.

Giuseppe Pelosi1, Aldo Scarpa, Michela Manzotti, Giulia Veronesi, Lorenzo Spaggiari, Filippo Fraggetta, Oscar Nappi, Elvira Benini, Felice Pasini, Davide Antonello, Antonio Iannucci, Patrick Maisonneuve, Giuseppe Viale.   

Abstract

We investigated 27 pleomorphic carcinomas of the lung for exon 1 K-ras gene mutations using polymerase chain reaction-single-strand conformation polymophism analysis and direct sequencing. All pleomorphic carcinomas were biphasic, that is, composed of an adeno-, squamous- or large-cell-carcinomatous component associated with a spindle- and/or giant-cell component. Of 27 cases, six (22%) showed K-ras codon 12 mutations, which is a figure higher than that previously reported on in pure sarcoma-like pleomorphic carcinomas. Five tumors displayed the same mutation in both the epithelial and the sarcomatoid components, whereas in one tumor the mutation was restricted to the epithelial component. All mutations occurred in smokers, and were transversions, including GGT (glycine) to TGT (cysteine) change in two cases, to GCT (alanine) in two and to GTT (valine) in two. No significant relationships were found between the occurrence and type of mutations and patients' survival or any other clinicopathological variable, suggesting that K-ras mutations are early events in the development of these tumors. Our results indicate that most, though not all, biphasic pleomorphic carcinomas of the lung are monoclonal in origin, and that cigarette smoking may have a causative role in the development of K-ras alterations in these tumors, as all mutations are transversions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990969     DOI: 10.1038/modpathol.3800058

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Sarcomatoid carcinomas of the lung--are these histogenetically heterogeneous tumors?

Authors:  Markus Blaukovitsch; Iris Halbwedl; Hannelore Kothmaier; Margit Gogg-Kammerer; Helmut H Popper
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

2.  Expression of adhesion molecules and transforming growth factor-β in pleomorphic carcinomas of the lung.

Authors:  Akira Okimura; Nobuyuki Terada; Masaki Hata; Kunimitsu Kawahara; Teruo Iwasaki; Mitsunori Oota; Hiroshi Hirano
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

3.  Use of gene expression profiling to direct in vivo molecular imaging of lung cancer.

Authors:  Jan Grimm; David G Kirsch; Stephen D Windsor; Carla F Bender Kim; Philip M Santiago; Vasilis Ntziachristos; Tyler Jacks; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-23       Impact factor: 11.205

4.  Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Domenico Galetta; Federica Perrone; Paola Braidotti; Michela Manzotti; Alessandra Fabbri; Lorenzo Spaggiari; Giulia Veronesi; Giuseppe Viale
Journal:  Virchows Arch       Date:  2011-01-06       Impact factor: 4.064

5.  Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.

Authors:  Soohyeon Lee; Youngwook Kim; Jong-Mu Sun; Yoon La Choi; Jhin Gook Kim; Young-Mog Shim; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Jung Ho Han; Myung-Ju Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2011-05-28       Impact factor: 4.553

6.  EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features.

Authors:  Xiaoli Jia; Gang Chen
Journal:  Contemp Oncol (Pozn)       Date:  2015-03-26

7.  New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.

Authors:  Takahiro Nakagomi; Taichiro Goto; Yosuke Hirotsu; Daichi Shikata; Yujiro Yokoyama; Rumi Higuchi; Kenji Amemiya; Kenichiro Okimoto; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Oncotarget       Date:  2018-01-31

8.  Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre.

Authors:  Suresh Kumar Bondili; Ravindra Nandhana; Aditya Dhanawat; Vanita Noronha; Amit Joshi; Vijay Maruti Patil; Nandini Menon; Rajiv Kumar Kaushal; Anuradha Choughule; Sabita S Jiwnani; Amit Janu; Kumar Prabhash
Journal:  Ecancermedicalscience       Date:  2022-08-08

9.  Sarcomatoid carcinoma of the lung: a model of resistance of chemotherapy.

Authors:  Imane Ouziane; Saber Boutayeb; Hind Mrabti; Issam Lalya; Mouna Rimani; Hassan Errihani
Journal:  N Am J Med Sci       Date:  2014-07

10.  Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

Authors:  Gavin M Wright; Hongdo Do; Jonathan Weiss; Naveed Z Alam; Vivek Rathi; Marzena Walkiewicz; Thomas John; Prudence A Russell; Alexander Dobrovic
Journal:  Oncotarget       Date:  2014-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.